Pfizer Inc
PFENYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 28, 2026Last filing: 10-Q on Nov 3, 2026Score 9/3047% above fair value
$28.06−0.41 (-1.44%)
Close on Nov 18, 2026Market cap $159.93BP/E 36.9Yield 6.13%
Pfizer Phase 3 clinical programs: 25 in Q2 2026, down 16.7% from a year earlier.
Latest, Q2 2026
25
Period ended Jun 28, 2026
Change on a year earlier
-16.7%
30 in Q2 2025
History
5 quarters
Since Q2 2025
Sources
4
Documents cited below
Where the Q2 2026 figure comes from
“Phase 1 Phase 2 Phase 3 Registration Total 37 25 2 95 R&D Projects 31 Pfizer Pipeline Snapshot as of August 4, 2026 Recent Approvals and Pipeline Highlights Pipeline represents progress of R&D Pfizer Inc. and Astellas Pharma Inc. announced that the U.S. Food and Drug Administration (FDA) has approved PADCEV ® (enfortumab vedotin-ejfv), a Nectin-4 directed”
Source: Pfizer Official Report — Q2 2026 Pipeline Update Final ↗
Reported in Form 8-K Earnings Release & Pfizer Quarterly Pipeline Update.
quarterly history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Phase 3 clinical programs | Year on year | Source |
|---|---|---|---|---|
| Q2 2026 | Jun 28, 2026 | 25 | -16.7% | Pfizer Official Report — Q2 2026 Pipeline Update Final ↗ |
| Q1 2026 | Mar 29, 2026 | 25 | – | Pfizer Official Report — Q1 2026 Pipeline Update vFinal 0 ↗ |
| Q4 2025 | Dec 31, 2025 | 30 | – | Pfizer Official Report — Q4 2025 Pipeline Update vFinal3 ↗ |
| Q3 2025 | Sep 28, 2025 | 30 | – | Pfizer Official Report — Q3 2025 Pipeline Update vFinal2 ↗ |
| Q2 2025 | Jun 29, 2025 | 30 | – | Pfizer Official Report — Q3 2025 Pipeline Update vFinal2 ↗ |
Cite this data
StockData. (2026). Pfizer Phase 3 clinical programs, quarterly Q2 2025–Q2 2026 [Data set]. Compiled from Pfizer SEC filings and investor materials. https://stockdatahq.com/stocks/pfe/kpis/pipe-p3
See every metric in the Pfizer KPI table. Data updated Nov 2, 2026.
See a number that looks wrong?